Mast Therapeutics Inc (NASDAQ:MSTX) has been downgraded to Market Perform in a report by Cowen and Company today.
- Updated: September 26, 2016
Having a price of $0.12, Mast Therapeutics Inc (NASDAQ:MSTX) traded -3.45% lower on the day. The last stock price is down -67.14% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the date range. MSTX has recorded a 50-day average of $0.43 and a two hundred day average of $0.37. Volume of trade was up over the average, with 24,914,275 shares of MSTX changing hands over the typical 7,673,100
Cowen and Company has downgraded Mast Therapeutics Inc (NASDAQ:MSTX) to Market Perform in a report released on 9/23/2016.
On 9/23/2016, Zacks Investment Research released a statement for Mast Therapeutics Inc (NASDAQ:MSTX) bumped up the target price from $0.00 to $0.25 that suggested an upside of 0.92%.
With a total market value of $0, Mast Therapeutics Inc has 52 week low of $0.10 and a 52 week high of $0.71 .
Brief Synopsis On Mast Therapeutics Inc (NASDAQ:MSTX)
Mast Therapeutics, Inc. is a biopharmaceutical company. The Company develops clinical-stage therapies for serious or life-threatening diseases with unmet needs. The Company focuses on developing new therapies for sickle cell disease, a chronic and genetic disorder classified as a rare, or orphan, disease in the United States of America and European Union, and for heart failure, a condition with an unmet need for treatment options. The Company's segment is engaged in the business of developing therapies for serious or life-threatening diseases. The Company focuses on its Molecular Adhesion and Sealant Technology (MAST) platform, to develop MST-188 (vepoloxamer) Injection, its lead product candidate. The Company also develops AIR001, a sodium nitrite solution for intermittent inhalation through nebulizer. The Company's AIR001 is in Phase II clinical development for the treatment of patients with HFpEF.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.